TCTAP 2012 Seoul, Korea April 26, 2012

# Best Preparation for Prevention of Stroke in Carotid Artery Stenting

Michael R. Jaff, DO, FACC

**Associate Professor of Medicine** 

Harvard Medical School

Chair, Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care

Boston, Massachusetts USA



## Michael R. Jaff, DO Conflicts of Interest

#### Consultant

- Abbott Vascular (non-compensated)
- Becker Venture Services Group
- Bluegrass Vascular Therapies
- Cordis Corporation(non-compensated)
- Covidien (non-compensated)
- Hansen Medical
- Medtronic (non-compensated)
- Micell, Incorporated
- Primacea
- Trivascular, Inc.
- Vortex

#### Equity

- Access Closure, Inc.
- Embolitech, Inc
- Hotspur, Inc
- Icon Interventional, Inc
- I.C.Sciences, Inc
- Janacare, Inc
- Northwind Medical, Inc.
- PQ Bypass, Inc.
- Primacea
- Sadra Medical
- TMI/Trireme, Inc
- Vascular Therapies, Inc.

#### **Board Member**

- VIVA Physicians (Not For Profit 501(c) 3 Organization)
  - www.vivapvd.com



#### Carotid Therapy


- Carotid endarterectomy performed for over 55 years
- Carotid artery stent performed for over 20 years
- Medical Therapy
  - Largely untested, specifically among patients being considered for revascularization

	No. of Procedures (Rate per 1000 Beneficiaries)			
Procedure	2003	2004	2005	2006
Carotid endarterectomy	88 698 (3.2)	85 349 (3.1)	76 387 (2.8)	69 920 (2.6)
Carotid stenting	NA	NA	8485 (0.3)	10 959 (0.4)
Total	88 698 (3.2)	85 349 (3.1)	84 872 (3.1)	80 879 (3.0)



# Carotid Revascularization in Medicare Population, 2010 Update








### Carotid Revascularization By Specialty, 2010

#### **Number of Carotid Stenting Procedures in Medicare**





#### Because of all the controversy...

#### Procedural Performance of CAS Must Be Flawless

- Step One
  - Don't choose patients who would be better treated either medically or with CEA



#### Get Experience On Who To Stent and How!




Influence of Site and Operator Characteristics on Carotid Artery Stent
Outcomes: Analysis of the CAPTURE 2 (Carotid ACCULINK/ACCUNET Post
Approval Trial to Uncover Rare Events) Clinical Study
William A. Gray, Kenneth A. Rosenfield, Michael R. Jaff, Seemant Chaturvedi, Lei
Peng, Patrick Verta, and CAPTURE 2 Investigators and Executive Committee

J. Am. Coll. Cardiol. Intv. 2011;4;235-246

doi:10.1016/j.jcin.2010.10.009




#### Stroke/Death Rates By Site Volume



J Am Coll Cardiol Intv 2011;4:235-46.



#### Stroke/Death Rates By Physician Volume







### Avoid Dense Lesion Calcification






## Avoid Marked ICA Tortuosity






## **Avoid Arch Challenges**





## Reassess During the Procedure---Consider Case Termination if Things Aren't Going Well







# Reassess During the Procedure---Consider Case Termination if Things Aren't Going Well


Sheath/Buddy Wires: What's Happening Here?







### **CREST Primary Endpoint\***





# 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery

	Symptomatic Patients		Asymptomation Patients	
	50% to 69% Stenosis	70% to 99% Stenosis*	70% to 99% Stenosis*	
Endarterectomy	Class I	Class I	Class IIa	
	LOE: B	LOE: A	LOE: A	
Stenting	Class I	Class I	Class IIb	
	LOE: B	LOE: B	LOE: B	



# Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: Executive summary

In 2008, the Society for Vascular Surgery published guidelines for the treatment of carotid bifurcation stenosis. Since that time, a number of prospective randomized trials have been completed and have shed additional light on the best treastment of extracranial carotid disease. This has prompted the Society for Vascular Surgery to form a committee to update and expand guidelines in this area. The review was done using the GRADE methodology.

In contrast to the multispecialty guidelines recently published, the committee recommends carotid endarterectomy (CEA) as first line treatment for most symptomatic patients with stenosis 50% to 99% and asymptomatic patients with stenosis 60% to 99%. The perioperative risk of stroke and death in asymptomatic patients must be below 3% to ensure benefit for the patient. Carotid artery stenting (CAS) should be reserved for symptomatic patients with stenosis 50% to 99% at high risk for CEA for anatomic or medical reasons. CAS is not recommended for asymptomatic patients at this time. Asymptomatic patients at high risk for intervention or with <3 years life expectancy should be considered for medical management as first line therapy.

In this Executive Summary, we only outline the specifics of the recommendations made in the six areas evaluated. The full text of these guidelines can be found on the on-line version of the Journal of Vascular Surgery at http://journals.elsevierhealth.com/periodicals/ymva. (J Vasc Surg 2011;54:832-6.)



# Wait....I Don't Get It---Wasn't The SVS Sponsors of the AHA Document?

# 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery



Is carotid artery stenting a fair alternative to carotid endarterectomy for symptomatic carotid artery stenosis? A commentary on the AHA/ASA guidelines

Kosmas I. Paraskevas, MD, a Frank J. Veith, MD, FACS, Thomas S. Riles, MD, FACS, and Wesley S. Moore, MD, FACS, Athens, Greece; New York, NY; Cleveland, Ohio; and Los Angeles, Calif

The recent guidelines by the American Heart Association/American Stroke Association (AHA/ASA) and several other associations recommended carotid artery stenting (CAS) as an alternative to carotid endarterectomy (CEA) for symptomatic patients (Class I; Level of Evidence: B). The term "alternative" may easily be misinterpreted as "equivalent" to justify the widespread use of CAS. However, current evidence indicates that for symptomatic patients, CAS produces inferior outcomes compared with CEA. It is likely that with technical improvements, better patient selection, and better physician experience, CAS outcomes will improve in the future. CAS may then become a fair alternative to CEA, at least in certain patient subgroups. Based on current evidence, however, we are not there yet and it seems unfair to spin the AHA/ASA guidelines to conclude that we are. (J Vasc Surg 2011;54:541-3.)



## Wait....Weren't Drs. Moore and Riles Members of the Writing Group for the AHA Guidelines?

#### Writing Committee Members

Thomas G. Brott, MD, Co-Chair\*
Jonathan L. Halperin, MD, Co-Chair†

Suhny Abbara, MD‡
J. Michael Bacharach, MD§
John D. Barr, MD||
Ruth L. Bush, MD, MPH
Christopher U. Cates, MD¶
Mark A. Creager, MD#
Susan B. Fowler, PhD\*\*
Gary Friday, MD††
Vicki S. Hertzberg, PhD

E. Bruce McIff, MD‡‡
Wesley S. Moore, MD
Peter D. Panagos, MD§§
Thomas S. Riles, MD||||
Robert H. Rosenwasser, MD¶¶
Allen J. Taylor, MD##

\*ASA Representative; †ACCF/AHA Representative and ACCF/AHA Task Force on Performance Measures Liaison; ‡SCCT Representative; §SVM Representative; #ACR, ASNR, and SNIS Representative; ¶SCAI Representative; #ACCF/AHA Task Force on Practice Guidelines Liaison; \*\*AANN Representative; ††AAN Representative; ‡‡SIR Representative; §§ACEP Representative; |||SVS Representative; ¶¶AANS and CNS Representative; ##SAIP Representative. Authors with no symbol by their name were included to provide additional content expertise apart from organizational representation.

Ahhhhh....now I see....we don't understand the difference between "alternative" and "equivalent"



#### So, When Controversy Rages over CAS....

- Choose patients wisely
- Gain experience
  - Physician
  - Site

Meticulous Procedural Performance

Don't be too proud to ask for help

